Hepatic Porphyrias

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2025-05-08
EMA Authorised: Givlaari (Givosiran) — Alnylam Netherlands B.V.
The European Medicines Agency authorised Givlaari (givosiran) for treatment of acute hepatic porphyrias, with orphan medicine status.